| Identification | Back Directory | [Name]
ESI 09 | [CAS]
263707-16-0 | [Synonyms]
ESI09
ESI-09
ESI 09
(E)-2-(5-(tert-butyl)isoxazol-3-yl)-N-(3-chlorophenyl)-2-oxoacetohydrazonoyl cyanide
(E)-3-(5-tert-butylisoxazol-3-yl)-2-(2-(3-chlorophenyl)hydrazono)-3-oxopropanenitrile
alpha-[(3-Chlorophenyl)hydrazono]-5-(1,1-dimethylethyl)-beta-oxo-3-isoxazolepropanenitrile
α-[2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-b-oxo-3-isoxazolepropanenitrile
α-[(2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo-3-isoxazolepropanenitrile
3-Isoxazolepropanenitrile, α-[2-(3-chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo-
3-?Isoxazolepropanenitr?ile, α-?[2-?(3-?chlorophenyl)?hydrazinylidene]?-?5-?(1,?1-?dimethylethyl)?-?β-?oxo- | [Molecular Formula]
C16H15ClN4O2 | [MDL Number]
MFCD00109218 | [MOL File]
263707-16-0.mol | [Molecular Weight]
330.77 |
| Chemical Properties | Back Directory | [Melting point ]
>175°C (dec.) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
powder | [color ]
, faint yellow to dark orange |
| Hazard Information | Back Directory | [Uses]
ESI 09 acts as an EPAC inhibitor, preventing EPAC-mediated insulin release form β-pancreatic cells. Selective control for EPAC over PKA and decreases migration and invasion of AsPc-1 and PANC-1 pancreatic cancer cells. | [Biochem/physiol Actions]
ESI-09 is a potent, specific inhibitor of EPAC (exchange protein directly activated by cAMP). ESI-09 inhibits EPAC1 and EPAC2 with IC50 values of 3.2 and 1.4 μM, respectively, with no activity against PKA at 25 μM. In pancreatic cell lines, the compound blocks phosphorylation of Akt and insulin secretion. ESI-09 inhibits migration of pancreatic cancer cell lines. | [in vivo]
Treatment with ESI-09 dramatically protects WT mice against R. australisinfection with much milder disease manifestations and significantly improves survival[2]. | [storage]
Store at -20°C |
|
|